Merck's Q2 earnings call highlighted the company's mixed performance, with 1% revenue growth despite a 4% unfavorable impact from foreign exchange. The company's guidance for 2012 remains unchanged, but the worsening foreign exchange situation may impact sales. The pipeline Updates, including Odanacatib and Suvorexant, are promising, but the loss of exclusivity for SINGULAIR in the US and Europe poses a significant challenge. Management's tone was optimistic, emphasizing the company's long-term growth strategy and commitment to R&D innovation, but also acknowledging the external pressures and uncertainties in the industry.

[1]